Surinabant

Surinabant
Clinical data
ATC code	none;
Identifiers
	IUPAC name 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide;
CAS Number	288104-79-0 ;
PubChem CID	9849616;
ChemSpider	8025329 ;
UNII	SF8R9VCB0X;
ChEMBL	ChEMBL189676 ;
CompTox Dashboard (EPA)	DTXSID2047357 ;
Chemical and physical data
Formula	C23H23BrCl2N4O
Molar mass	522.27 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(NN1CCCCC1)c4nn(c2ccc(Cl)cc2Cl)c(c3ccc(Br)cc3)c4CC;
	InChI InChI=1S/C23H23BrCl2N4O/c1-2-18-21(23(31)28-29-12-4-3-5-13-29)27-30(20-11-10-17(25)14-19(20)26)22(18)15-6-8-16(24)9-7-15/h6-11,14H,2-5,12-13H2,1H3,(H,28,31) ; Key:HMXDWDSNPRNUKI-UHFFFAOYSA-N ;
	(what is this?) (verify)

Surinabant (SR147778) is a cannabinoid receptor type 1 antagonist developed by Sanofi-Aventis.^[1] It is being investigated as a potential treatment for nicotine addiction, to assist smoking cessation. It may also be developed as an anorectic drug to assist with weight loss, however there are already several CB₁ antagonists or inverse agonists on the market or under development for this application,^[2] so surinabant is at present mainly being developed as an anti-smoking drug,^[3] with possible application in the treatment of other addictive disorders such as alcoholism.^[4]^[5] Other potential applications such as treatment of ADHD have also been proposed.^[6]

Quick Facts Clinical data, ATC code ...

A dose ranging study was done for smoking cessation^[7] in 2012; it did not improve success rate, but reduced weight gain. Inhibition of THC effects on heart rate was seen at 20 mg and 60 mg but not 5 mg.^[8]

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

Surinabant

See also

References

Wikiwand - on